Follow
Matthew R Sydes
Matthew R Sydes
MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College
Verified email at ucl.ac.uk - Homepage
Title
Cited by
Cited by
Year
Practical methods for incorporating summary time-to-event data into meta-analysis
JF Tierney, LA Stewart, D Ghersi, S Burdett, MR Sydes
Trials 8 (1), 1-16, 2007
46082007
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage …
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
The Lancet 387 (10024), 1163-1177, 2016
17412016
Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial
A Cuschieri, S Weeden, J Fielding, J Bancewicz, J Craven, V Joypaul, ...
British journal of cancer 79 (9), 1522-1530, 1999
17021999
Abiraterone for prostate cancer not previously treated with hormone therapy
ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ...
New England Journal of Medicine 377 (4), 338-351, 2017
13742017
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
DP Dearnaley, MR Sydes, JD Graham, EG Aird, D Bottomley, RA Cowan, ...
The lancet oncology 8 (6), 475-487, 2007
10122007
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ...
The Lancet 392 (10162), 2353-2366, 2018
7612018
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
P Warde, M Mason, K Ding, P Kirkbride, M Brundage, R Cowan, ...
The Lancet 378 (9809), 2104-2111, 2011
6222011
High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial
HC Schouten, W Qian, S Kvaloy, A Porcellini, H Hagberg, HE Johnsen, ...
Journal of clinical oncology 21 (21), 3918-3927, 2003
5992003
Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ...
European urology 73 (2), 178-211, 2018
4612018
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial
DP Dearnaley, G Jovic, I Syndikus, V Khoo, RA Cowan, JD Graham, ...
The lancet oncology 15 (4), 464-473, 2014
4492014
Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019)
ND James, MR Spears, NW Clarke, DP Dearnaley, JS De Bono, J Gale, ...
European urology 67 (6), 1028-1038, 2015
4432015
Perioperative β-blockade (Pobble) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial
JT Powell, POBBLE Trial Investigators
Journal of Vascular Surgery 41 (4), 602-609, 2005
4292005
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of …
CL Vale, S Burdett, LHM Rydzewska, L Albiges, NW Clarke, D Fisher, ...
The lancet oncology 17 (2), 243-256, 2016
4252016
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma …
IJ Lewis, MA Nooij, J Whelan, MR Sydes, R Grimer, PCW Hogendoorn, ...
Journal of the National Cancer Institute 99 (2), 112-128, 2007
3972007
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study
GM Mead, MR Sydes, J Walewski, A Grigg, CS Hatton, P Norbert, ...
Annals of Oncology 13 (8), 1264-1274, 2002
3692002
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label …
NM Marina, S Smeland, SS Bielack, M Bernstein, G Jovic, MD Krailo, ...
The Lancet Oncology 17 (10), 1396-1408, 2016
3582016
Adaptive designs in clinical trials: why use them, and how to run and report them
P Pallmann, AW Bedding, B Choodari-Oskooei, M Dimairo, L Flight, ...
BMC medicine 16 (1), 1-15, 2018
3472018
Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with …
RJ Sylvester, W Oosterlinck, S Holmang, MR Sydes, A Birtle, ...
European urology 69 (2), 231-244, 2016
3152016
Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good …
SS Bielack, S Smeland, JS Whelan, N Marina, G Jovic, JM Hook, ...
Journal of Clinical Oncology 33 (20), 2279, 2015
3072015
Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer
W Xie, MM Regan, M Buyse, S Halabi, PW Kantoff, O Sartor, H Soule, ...
Journal of Clinical Oncology 35 (27), 3097-3104, 2017
3022017
The system can't perform the operation now. Try again later.
Articles 1–20